AR059767A1 - Profarmacos de analogos de cc-1065 y sus conjugados, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende y el uso de estos para la fabricacion de un medicamento para el tratamiento del cancer. - Google Patents
Profarmacos de analogos de cc-1065 y sus conjugados, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende y el uso de estos para la fabricacion de un medicamento para el tratamiento del cancer.Info
- Publication number
- AR059767A1 AR059767A1 ARP070100932A ARP070100932A AR059767A1 AR 059767 A1 AR059767 A1 AR 059767A1 AR P070100932 A ARP070100932 A AR P070100932A AR P070100932 A ARP070100932 A AR P070100932A AR 059767 A1 AR059767 A1 AR 059767A1
- Authority
- AR
- Argentina
- Prior art keywords
- prodrug
- subunit
- group
- prodrugs
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Profármacos de análogos del antibiotico CC-1065 antitumoral que tiene un grupo protector escindible que contiene un ácido sulfonico que contiene carbamato de fenilo, en los que el grupo protector confiere mayor solubilidad en agua respecto al profármaco, y en los que el profármaco también tiene un resto tal como un sulfuro o un disulfuro, que pueden conjugarse a un reactivo de union a células tal como un anticuerpo. El uso terapéutico de tales conjugados profármacos se describe también; tales profármacos de agentes citotoxicos tienen uso terapéutico porque pueden liberar profármacos citotoxicos a una poblacion celular específica para conversion enzimática a fármacos citotoxicos de una manera dirigida. Reivindicacion 2: Un profármaco de acuerdo con la reivindicacion 1, en donde el análogo de CC-1065 se selecciona del grupo consistente en análogos formados a partir de una primera subunidad de formula (1) covalentemente enlazada a una segunda subunidad de la formula (2), (3), (4), (5), (6), (7), (8), (9), (10) o (11) a través de un enlace amida desde el grupo amino secundario del resto pirrolico de la primera subunidad al carboxilo C-2 de la segunda subunidad, en las que Y representa un grupo eliminable seleccionado de un haluro (fluoruro, cloruro, bromuro o yoduro), metanosulfonato, para-toluenosulfonato, trifluorometanosulfonato, mononitro- o dinitrofenolato; en donde R, R', R1-R6 son cada uno independientemente hidrogeno, alquilo C1-3 lineal, metoxi, hidroxilo, amino primario, amino secundario, amino terciario, o amido o un enlazador que proporciona enlace del profármaco a un agente de union a células, con tal de que al menos uno de R, R', R1-R6 sea un enlazador y en donde R7 es dicho grupo protector de ácido sulfonico que contiene carbamato, o sus sales farmacéuticamente aceptables, hidratos, o sales hidratadas, o las estructuras cristalinas polimorficas de estos compuestos o sus isomeros opticos, racematos, diastereoisomeros o enantiomeros.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06290379A EP1832577A1 (en) | 2006-03-07 | 2006-03-07 | Improved prodrugs of CC-1065 analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR059767A1 true AR059767A1 (es) | 2008-04-30 |
Family
ID=36679356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070100932A AR059767A1 (es) | 2006-03-07 | 2007-03-06 | Profarmacos de analogos de cc-1065 y sus conjugados, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende y el uso de estos para la fabricacion de un medicamento para el tratamiento del cancer. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US8012978B2 (es) |
| EP (2) | EP1832577A1 (es) |
| JP (1) | JP2009529030A (es) |
| KR (1) | KR20080106919A (es) |
| AR (1) | AR059767A1 (es) |
| AU (1) | AU2007222123A1 (es) |
| BR (1) | BRPI0708654A2 (es) |
| CA (1) | CA2642870A1 (es) |
| DO (1) | DOP2007000041A (es) |
| EA (1) | EA200870327A1 (es) |
| IL (1) | IL193673A0 (es) |
| MA (1) | MA30322B1 (es) |
| MX (1) | MX2008011431A (es) |
| NO (1) | NO20083910L (es) |
| PE (1) | PE20080691A1 (es) |
| TW (1) | TW200813028A (es) |
| UY (1) | UY30190A1 (es) |
| WO (1) | WO2007102069A1 (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2163256T3 (en) | 2001-05-11 | 2015-12-07 | Ludwig Inst For Cancer Res Ltd | Specific binding proteins and use thereof |
| US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
| US6756397B2 (en) * | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| NZ574215A (en) | 2006-07-18 | 2012-07-27 | Sanofi Aventis | Antagonist antibody against epha2 for the treatment of cancer |
| ES2609094T3 (es) * | 2007-01-25 | 2017-04-18 | Dana-Farber Cancer Institute, Inc. | Uso de anticuerpos anti-EGFR en el tratamiento de enfermedades mediadas por un EGFR mutante |
| CN101688229B (zh) * | 2007-03-15 | 2013-06-12 | 路德维格癌症研究所 | 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途 |
| US9901567B2 (en) | 2007-08-01 | 2018-02-27 | Syntarga B.V. | Substituted CC-1065 analogs and their conjugates |
| US9283276B2 (en) | 2007-08-14 | 2016-03-15 | Ludwig Institute For Cancer Research Ltd. | Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof |
| WO2009059309A2 (en) * | 2007-11-01 | 2009-05-07 | Panacea Pharmaceuticals, Inc. | Furin-cleavable peptide linkers for drug-ligand conjugates |
| HUE035798T2 (en) | 2008-11-03 | 2018-05-28 | Syntarga Bv | CC-1065 analogues and conjugates |
| FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
| FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
| US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
| AR078470A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | Anticuerpos que se unen especificamente al receptor epha2 |
| UY32913A (es) | 2009-10-02 | 2011-04-29 | Sanofi Aventis | Nuevos maitansinoides y el uso de dichos maitansinoides para preparar conjugados con un anticuero |
| PL3056203T3 (pl) | 2010-04-21 | 2018-06-29 | Syntarga B.V. | Koniugaty analogów CC-1065 i łączników dwufunkcyjnych |
| FR2963007B1 (fr) | 2010-07-26 | 2013-04-05 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application therapeutique |
| EP2830614B1 (en) * | 2012-03-30 | 2017-04-26 | The Scripps Research Institute | Cyclic prodrugs of duocarmycin analogs |
| EP3210627B1 (en) | 2012-07-12 | 2022-12-21 | Hangzhou Dac Biotech Co., Ltd | Conjugates of cell binding molecules with cytotoxic agents |
| ES2701076T3 (es) | 2012-11-24 | 2019-02-20 | Hangzhou Dac Biotech Co Ltd | Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células |
| WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
| WO2015104385A2 (en) | 2014-01-10 | 2015-07-16 | Synthon Biopharmaceuticals B.V. | Duocarmycin adcs showing improved in vivo antitumor activity |
| MY177390A (en) | 2014-01-10 | 2020-09-14 | Byondis Bv | Method for purifying cys-linked antibody-drug conjugates |
| CA2935430C (en) | 2014-01-10 | 2018-09-18 | Synthon Biopharmaceuticals B.V. | Duocarmycin adcs for use in treatment of endometrial cancer |
| US10464955B2 (en) | 2014-02-28 | 2019-11-05 | Hangzhou Dac Biotech Co., Ltd. | Charged linkers and their uses for conjugation |
| CA2991973C (en) | 2015-07-12 | 2021-12-07 | Suzhou M-Conj Biotech Co., Ltd. | Bridge linkers for conjugation of a cell-binding molecule |
| US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
| TW201808336A (zh) | 2016-05-11 | 2018-03-16 | 賽諾菲公司 | 用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案 |
| US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
| KR20220150408A (ko) | 2016-11-14 | 2022-11-10 | 항저우 디에이씨 바이오테크 씨오, 엘티디 | 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용 |
| US11932650B2 (en) | 2017-05-11 | 2024-03-19 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| WO2020247054A1 (en) | 2019-06-05 | 2020-12-10 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| EP4126833A1 (en) * | 2020-03-23 | 2023-02-08 | Helmholtz-Zentrum für Infektionsforschung GmbH | N-phenyl-3-mercaptopropanamide derivatives as metallo-beta-lactamase inhibitors for the treatment of bacterial infections |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5278324A (en) * | 1990-08-28 | 1994-01-11 | Virginia Tech Intellectual Properties, Inc. | Water soluble derivatives of taxol |
| CA2076465C (en) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Cell binding agent conjugates of analogues and derivatives of cc-1065 |
| US5646298A (en) | 1995-06-07 | 1997-07-08 | Procoron, Inc. | Cyclopropylindole prodrugs |
| US6756397B2 (en) * | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| US6534660B1 (en) | 2002-04-05 | 2003-03-18 | Immunogen, Inc. | CC-1065 analog synthesis |
-
2006
- 2006-03-07 EP EP06290379A patent/EP1832577A1/en not_active Withdrawn
-
2007
- 2007-03-05 PE PE2007000236A patent/PE20080691A1/es not_active Application Discontinuation
- 2007-03-06 KR KR1020087021749A patent/KR20080106919A/ko not_active Application Discontinuation
- 2007-03-06 MX MX2008011431A patent/MX2008011431A/es not_active Application Discontinuation
- 2007-03-06 AU AU2007222123A patent/AU2007222123A1/en not_active Abandoned
- 2007-03-06 DO DO2007000041A patent/DOP2007000041A/es unknown
- 2007-03-06 EP EP07713102A patent/EP1993999A1/en not_active Withdrawn
- 2007-03-06 CA CA002642870A patent/CA2642870A1/en not_active Abandoned
- 2007-03-06 UY UY30190A patent/UY30190A1/es not_active Application Discontinuation
- 2007-03-06 EA EA200870327A patent/EA200870327A1/ru unknown
- 2007-03-06 JP JP2008557845A patent/JP2009529030A/ja not_active Withdrawn
- 2007-03-06 WO PCT/IB2007/000521 patent/WO2007102069A1/en active Application Filing
- 2007-03-06 TW TW096107668A patent/TW200813028A/zh unknown
- 2007-03-06 AR ARP070100932A patent/AR059767A1/es unknown
- 2007-03-06 BR BRPI0708654-7A patent/BRPI0708654A2/pt not_active Application Discontinuation
-
2008
- 2008-08-25 IL IL193673A patent/IL193673A0/en unknown
- 2008-09-04 US US12/204,082 patent/US8012978B2/en not_active Expired - Fee Related
- 2008-09-12 NO NO20083910A patent/NO20083910L/no not_active Application Discontinuation
- 2008-09-29 MA MA31261A patent/MA30322B1/fr unknown
-
2011
- 2011-07-15 US US13/184,255 patent/US20110280890A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1993999A1 (en) | 2008-11-26 |
| NO20083910L (no) | 2008-12-01 |
| UY30190A1 (es) | 2008-10-31 |
| US8012978B2 (en) | 2011-09-06 |
| AU2007222123A1 (en) | 2007-09-13 |
| WO2007102069A1 (en) | 2007-09-13 |
| PE20080691A1 (es) | 2008-06-04 |
| US20110280890A1 (en) | 2011-11-17 |
| EP1832577A1 (en) | 2007-09-12 |
| IL193673A0 (en) | 2009-05-04 |
| JP2009529030A (ja) | 2009-08-13 |
| BRPI0708654A2 (pt) | 2011-06-07 |
| MA30322B1 (fr) | 2009-04-01 |
| KR20080106919A (ko) | 2008-12-09 |
| US20090028821A1 (en) | 2009-01-29 |
| DOP2007000041A (es) | 2007-10-31 |
| TW200813028A (en) | 2008-03-16 |
| MX2008011431A (es) | 2008-09-22 |
| EA200870327A1 (ru) | 2009-02-27 |
| CA2642870A1 (en) | 2007-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR059767A1 (es) | Profarmacos de analogos de cc-1065 y sus conjugados, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende y el uso de estos para la fabricacion de un medicamento para el tratamiento del cancer. | |
| ES2609084T3 (es) | Derivados de fenoxi y feniltio sustituidos para tratar trastornos proliferativos | |
| CU20110216A7 (es) | Derivados aminobutíricos sustituidos como inhibidores de neprilisina | |
| CO6470847A2 (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
| ECSP109905A (es) | Moduladores de receptor 7 tipo toll | |
| AR063165A1 (es) | Derivados de acido boronico como inhibidores de amidihidrolasa de acidos grasos. composiciones farmaceuticas. | |
| AR028985A1 (es) | Compuestos derivados de quinolin-2-ona- sustituidos con heteroarilo utiles como agentes anticancerigenos, procedimiento de tratamiento de enfermedades utilizando dicho compuesto, composicion farmaceutica que lo contiene | |
| CR20120237A (es) | Derivados del ácido carbamoil-metil-amino-acético sustituido como inhibidores de nep novedosos | |
| TW200744587A (en) | Azaindole derivatives exhibiting PGD2 receptor antagonism | |
| AR041635A1 (es) | Compuestos de 4-piperazinilbencenosulfonilindoles, preparacion de los mismos y composiciones farmaceuticas que los contienen | |
| CO6362010A2 (es) | Moduladores de los receptores tipo toll | |
| ECSP088731A (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen | |
| UY29312A1 (es) | Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones | |
| AR047685A1 (es) | Derivados de hexaciclopenta[c]pirrol como activadores de sistemas histaminicos centrales, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen y medicamentos para el tratamiento de neuropatologias asociadas al envejecimiento cerebral | |
| AR064253A1 (es) | Compuestos de biciclocarboxiamida sustituidos composiciones farmaceuticas y una combinacion que los incluye y su uso en fabaricacion de un medicamento para el tratamiento de enfermedades mediadas por la actividad del receptor vr1 | |
| AR063119A1 (es) | Derivados de piridinonas sustituidas, composiciones farmaceuticas que los contienen y usos como antagonistas en trastornos asociados a receptores del tipo i de la hormona de melanina(mch-1 o mchr-1) | |
| AR073845A1 (es) | Derivados de acido l-glutamico y l-glutamina marcados con [f-18] (i), su uso y procedimiento para su preparacion y composiciones farmaceuticas | |
| BRPI0310032B8 (pt) | derivados de benzoxazina, seus usos e seus processos de produção, e composição farmacêutica | |
| AR074593A1 (es) | Benzotiazol amidas para la deteccion del peptido beta amiloide | |
| ES2621802T3 (es) | Sulfóxidos alfa, beta-insaturados para tratar trastornos proliferativos | |
| AR045517A1 (es) | Procedimiento para la sintesis de perindopril y de sus sales farmaceuticamente aceptables | |
| AR078415A1 (es) | Derivados de acido 2- mercaptociclopentanocarboxilico, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR072389A1 (es) | Compuesto de 3-cianopirrolidinil-fenil-oxazolidinona, procedimiento para prepararlo, composicion farmaceutica que la comprende y sus usos | |
| PE20030345A1 (es) | 3,5-dihidroxi-2,2-dimetil-valeroamidas protegidas para la sintesis de epotilonas y derivados y un procedimiento para su preparacion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |